Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 3/20 | 1.00 |
| ▸ | PRMT5 | O14744 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | PLAU | P00749 | 4/20 | 0.58 |
| ▸ | PLG | P00747 | 1/20 | 0.58 |
| ▸ | PLAT | P00750 | 1/20 | 0.58 |
| ▸ | KLK1 | P06870 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MASP2 | O00187 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 7/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 6/20 | 0.52 |
| ▸ | F12 | P00748 | 1/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stilbamidine SCHEMBL889782 | 1.00 | PRMT1 (1.00) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| Stilbamidine SCHEMBL3932459 | 0.97 | PRMT1 (0.95) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| Stilbamidine SCHEMBL871695 | 0.95 | PRMT1 (0.91) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| SCHEMBL428474 | 0.91 | PRMT1 (0.83) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| SCHEMBL428473 | 0.91 | PRMT1 (0.83) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| Hydrochloric Acid SCHEMBL11333159 | 0.89 | PRMT1 (0.79) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| Hydrochloric Acid SCHEMBL11333164 | 0.89 | PRMT1 (0.79) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| SCHEMBL2521983 | 0.89 | PRMT1 (0.79) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| SCHEMBL23902148 | 0.87 | PRMT1 (0.76) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| SCHEMBL2520059 | 0.85 | ALDH1A1 (0.73) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1053 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | UNIVERSITY OF VIRGINIA | 2022-06-02 | — | — | US | claimed |
| WO-2020198601-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-10-01 | — | — | WO | claimed |
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | claimed |
| US-9802951-B2 | Biologically active taxane analogs and methods of treatment by oral administration | TAPESTRY PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | claimed |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2017-10-12 | — | — | US | claimed |
| EP-2275107-B1 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INT (DE) | 2016-10-05 | — | — | EP | claimed |
| US-9358319-B2 | Cement products and methods of making and using the same | PIONEER SURGICAL TECHNOLOGY, INC. (US) | 2016-06-07 | — | — | US | claimed |
| EP-2547769-B1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | ELITECHGROUP B V (NL) | 2016-04-06 | — | — | EP | claimed |
| US-20150265610-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-24 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-6492346-B1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | claimed |
| US-20020165261-A1 | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | ZALICUS INC. | 2002-11-07 | — | — | US | claimed |
| EP-1253924-A1 | NITRATE SALTS OF ANTIMICROBIAL AGENTS | NICOX S.A. (FR) | 2002-11-06 | — | — | EP | claimed |
| WO-2002058684-A2 | COMBINATIONS OF DRUGS (E.G., CHLORPROMAZINE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2002-08-01 | — | — | WO | claimed |
| WO-2002058697-A1 | COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2002-08-01 | — | — | WO | claimed |
| US-20020065227-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT PHARMACEUTICALS, INC. | 2002-05-30 | — | — | US | claimed |
| WO-2001074898-A2 | CHARGED COMPOUNDS COMPRISING A NUCLEIC ACID BINDING MOIETY AND USES THEREFOR | GENESOFT, INC. (US) | 2001-10-11 | — | — | WO | claimed |
| WO-2001054691-A1 | NITRATE SALTS OF ANTIMICROBIAL AGENTS | NICOX, S.A. (FR) | 2001-08-02 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165261-A1 | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | DHFR, DPYD, VHL | PRMT1 1862/4885PRMT5 1021/4885ALDH1A1 346/4885 |
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | DDIT3, PRMT3, PRMT1 | PRMT1 3/4885PRMT5 7/4885ALDH1A1 2651/4885 |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | PRMT1 2283/4885PRMT5 2403/4885ALDH1A1 840/4885 |
| US-20150265610-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BAX, BCL2, VEGFA | PRMT1 1828/4885PRMT5 1508/4885ALDH1A1 2021/4885 |
| US-20020065227-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | POLRMT, PCNA, SARS1 | PRMT1 1843/4885PRMT5 2580/4885ALDH1A1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.